Tata Memorial Study Finds Ultra-Low Dose Immunotherapy Improves Survival, Cuts Cancer Treatment Costs
Published on: Feb. 4, 2026, 3:09 a.m. | Source: Free Press Journal
A Phase III trial by Tata Memorial Hospital found that ultra-low dose immunotherapy significantly improved survival and quality of life in relapsed cancer patients while cutting costs by up to 90%. Lead author Dr Kumar Prabhash said the findings could expand access to life-saving treatment under public health schemes.
